Skip to main
ZBH
ZBH logo

ZBH Stock Forecast & Price Target

ZBH Analyst Ratings

Based on 17 analyst ratings
Hold
Strong Buy 18%
Buy 24%
Hold 47%
Sell 6%
Strong Sell 6%

Bulls say

Zimmer Biomet Holdings has demonstrated a robust financial performance, with key segments such as knees and hips experiencing growth rates of 5.3% and 3.8% respectively on a constant currency basis, signaling solid demand in the orthopedic market. The company has successfully executed a turnaround strategy that is supported by recent product innovations and strategic mergers and acquisitions, contributing to an overall upward trend in top-line growth. Additionally, Zimmer Biomet's healthy balance sheet and alignment with fiscal year 2025 revenue growth targets further underscore a promising outlook for the firm in the competitive orthopedic space.

Bears say

Zimmer Biomet Holdings (ZBH) is facing challenges with flat average selling prices (ASP) projected for FY25, coupled with a modest headwind from selling day differences impacting growth. The company’s recent performance reveals lower growth rates for its Knee segment relative to peers, with the Hip segment showing the weakest performance, leading to a downward revision of operating margins for Q3 and Q4. Additionally, ZBH’s updated guidance highlights persistent weaknesses in restorative therapies and slower organic growth, particularly in overseas markets, contributing to a negative outlook given the firm's execution difficulties and competitive pressures.

ZBH has been analyzed by 17 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 24% recommend Buy, 47% suggest Holding, 6% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zimmer Biomet Hlds (ZBH) Forecast

Analysts have given ZBH a Hold based on their latest research and market trends.

According to 17 analysts, ZBH has a Hold consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $106.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $106.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zimmer Biomet Hlds (ZBH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.